Back

Expanding therapeutic options for lowering LDL-c: Where will bempedoic acid and inclisiran contribute.

27 August 2021 (13:20 - 13:36)
Organised by:
Congress Presentation Part of: Redefining intensive LDL-c management in high risk patients: The case for combination therapy Risk Factors and Prevention Open Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)

3 More presentations in this session

Presentation thumbnail
LDL-c in the management of high CV risk: Changing the paradigm for prevention.
Professor K. Ray (London, GB)
Video
Presentation thumbnail
The urgency to treat LDL-c post MI: The role of PCSK9 mAbs in reaching goals.
Professor D. Connolly (Birmingham, GB)
Video
Presentation thumbnail
Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?
Professor J. Kastelein (Amsterdam, NL)
Video

Access the full session

Session thumbnail
Redefining intensive LDL-c management in high risk patients: The case for combination therapy
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 13:20 CET
You may be interested in
thumbnail
ESC TV Today
Episode 7: Fluid restriction, bed rest, leg compression in AHF - Device-detected atrial fibrillation